Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
46. |
ECCT/15/08/01 | Rifapentine During Intensive Phase TB Treatment Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: a randomized, open-label, controlled, phase 3 clinical trial |
Principal Investigator(s) 1. Elisha Ochieng Okeyo Site(s) in Kenya KEMRICDC, KISUMU, KENYA |
View |
47. |
ECCT/20/09/02 | BEe-HIVe B-ENHANCEMENT OF HBV VACCINATIONIN PERSONS LIVING WITH HIV (BEe-HIVe) EVALUATION OF HEPLISAV-B,A5379 |
Principal Investigator(s) 1. JOSPHAT KOSGEI Site(s) in Kenya KEMRI/KERICHO CLINIC RESEARCH CENTRE |
View |
48. |
ECCT/19/12/02 | VPM1002 Phase III PoI A multicenter, Phase III double blind, randomized active controlled study to evaluate efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in newborn infants. |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI-CRDR Nairobi (Nairobi City county) 2. KEMRI-CRDR Siaya (Siaya county) |
View |
49. |
ECCT/15/02/03 | IVERMAL study Efficacy and safety of high-dose Ivermectin for reducing malaria transmission: A dose finding study |
Principal Investigator(s) 1. Menno Roderick Smit Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) (Kisumu county) 2. Kisumu District Hospital (KDH), (Kisumu county) 3. Siaya District Hospital (Siaya county) 4. Vihiga District Hospital (Vihiga county) |
View |
50. |
ECCT/23/04/05 | BiMVaC01 A randomised, controlled clinical trial to assess and compare the immunogenicity, safety and reactogenicity of the bivalent Omicron BA.4/BA.5 adapted, and the original Wuhan-Hu-1-strain, BNT162b2 COVID-19 vaccine formulations in healthy unvaccinated East African adults. |
Principal Investigator(s) 1. NDUNGU FRANCIS 2. Said Jongo Site(s) in Kenya KEMRI-CGMRC Kilifi |
View |